| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...984197D |
| P356 | DOI | 10.1371/JOURNAL.PONE.0084197 |
| P932 | PMC publication ID | 3880287 |
| P698 | PubMed publication ID | 24404155 |
| P5875 | ResearchGate publication ID | 259631862 |
| P50 | author | Claudia Denkinger | Q87150820 |
| Madhukar Pai | Q30332033 | ||
| P2093 | author name string | David W Dowdy | |
| P2860 | cites work | Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India | Q70719801 |
| Initial default from tuberculosis treatment: how often does it happen and what are the reasons? | Q81432304 | ||
| Assessment of doctors' knowledge regarding tuberculosis management in Lucknow, India: a public-private sector comparison | Q84135476 | ||
| Mismanagement of tuberculosis in India: Causes, consequences, and the way forward | Q22241150 | ||
| Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults | Q24201466 | ||
| Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru | Q28202372 | ||
| A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society | Q28267420 | ||
| Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis | Q28476120 | ||
| Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis | Q28476125 | ||
| Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation | Q28485280 | ||
| Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study | Q29615717 | ||
| Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. | Q33977319 | ||
| Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009 | Q33988089 | ||
| Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. | Q34131132 | ||
| Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach | Q34562015 | ||
| Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations | Q34598512 | ||
| Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa | Q35452446 | ||
| Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis | Q35771345 | ||
| Isoniazid preventive therapy and risk for resistant tuberculosis | Q36029457 | ||
| HIV infection and multidrug-resistant tuberculosis: the perfect storm | Q36877246 | ||
| Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa | Q37053021 | ||
| Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. | Q37108540 | ||
| Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness | Q37120860 | ||
| GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis | Q37211510 | ||
| Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis | Q37216059 | ||
| Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. | Q37373820 | ||
| Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries | Q38059894 | ||
| Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. | Q38160741 | ||
| Controlled chemoprophylaxis trials in tuberculosis. A general review | Q39002300 | ||
| Default during TB diagnosis: quantifying the problem | Q39132502 | ||
| The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection | Q39566509 | ||
| ??? | Q26824091 | ||
| The competitive cost of antibiotic resistance in Mycobacterium tuberculosis | Q40311130 | ||
| Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease | Q41311704 | ||
| Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis | Q41350226 | ||
| Results in pulmonary tuberculosis patients under various treatment program conditions | Q44201639 | ||
| Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries | Q44528463 | ||
| Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance | Q45064609 | ||
| The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis | Q45115476 | ||
| Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. | Q46029821 | ||
| Developing and interpreting models to improve diagnostics in developing countries. | Q46796891 | ||
| Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study | Q46863163 | ||
| Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. | Q50636875 | ||
| Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. | Q53652816 | ||
| Primary multidrug-resistant tuberculosis--Ivanovo Oblast, Russia, 1999. | Q54078882 | ||
| The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of c | Q56900086 | ||
| Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands | Q59362511 | ||
| First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons | Q61680488 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| rifampicin | Q422652 | ||
| isoniazid | Q423169 | ||
| P304 | page(s) | e84197 | |
| P577 | publication date | 2014-01-03 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? | |
| P478 | volume | 9 |
| Q42398699 | 7th Union Europe Conference on Lung Health, 22-24 June 2016, Bratislava (Slovakia): a delegate report |
| Q51361440 | Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. |
| Q38265418 | Evaluation of the Cepheid Xpert MTB/RIF assay |
| Q28548604 | Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal |
| Q27016579 | Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy |
| Q33595994 | Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance |
| Q52679975 | Isoniazid Monoresistance: A Precursor to Multidrug-Resistant Tuberculosis? |
| Q33820505 | Isoniazid-resistant tuberculosis: a cause for concern? |
| Q26778117 | Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies |
| Q28547835 | Rapid Molecular Detection of Multidrug-Resistant Tuberculosis by PCR-Nucleic Acid Lateral Flow Immunoassay |
| Q35588123 | Target product profile of a molecular drug-susceptibility test for use in microscopy centers |
| Q58079470 | The Importance of Heterogeneity to the Epidemiology of Tuberculosis |
| Q61810684 | The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study |
| Q51614972 | To build better tuberculosis diagnostics, look for 'biosignatures'. |
Search more.